Last updated: September 5, 2026
WAL-ZYR is a private-label cetirizine hydrochloride 10 mg OTC antihistamine. Its commercial opportunity is not exclusivity-based. The product competes on low cost, retailer distribution, dependable tablet performance, packaging, supply reliability, and potential line extensions such as rapid-dissolve, liquid, chewable, or preservative-free formats. Cetirizine’s core active-ingredient patents and regulatory exclusivity have expired, and generic entry risk is effectively established.
WAL-ZYR Excipient Strategy and Commercial Opportunities
What is WAL-ZYR and which active ingredient does it contain?
WAL-ZYR is Walgreens’ private-label cetirizine product, generally marketed as cetirizine hydrochloride 10 mg tablets for relief of allergy symptoms and hives. Cetirizine is a second-generation H1 antihistamine.
| Attribute |
WAL-ZYR assessment |
| Brand owner or retailer |
Walgreens private-label retail brand |
| Active ingredient |
Cetirizine hydrochloride |
| Typical strength |
10 mg per tablet |
| Therapeutic category |
OTC oral antihistamine |
| Reference brand |
Zyrtec |
| Regulatory route |
OTC monograph or approved generic-equivalent pathway, depending on the specific product |
| Dosage form |
Usually film-coated tablet |
| Prescription requirement |
No, for standard OTC presentations |
| Patent status |
Core cetirizine composition and principal product patents expired |
| Orange Book position |
WAL-ZYR is generally not an innovator Orange Book product |
| Primary commercial drivers |
Cost, retailer access, supply, package count, formulation quality and consumer preference |
The exact inactive-ingredient profile can vary by manufacturer, NDC, dosage form and production site. A current package label or DailyMed record controls for any specific WAL-ZYR SKU.
What excipients are used in WAL-ZYR tablets?
A conventional cetirizine tablet uses excipients for direct compression or granulation, disintegration, lubrication, film coating and physical stability. Publicly available cetirizine tablet labels commonly identify some or all of the following excipient classes:
| Excipient class |
Typical function |
Commercial relevance |
| Microcrystalline cellulose |
Filler and compression aid |
Supports tablet hardness and low-cost manufacturing |
| Lactose monohydrate |
Filler and binder |
Reduces cost but creates a lactose-related label consideration |
| Crospovidone |
Superdisintegrant |
Promotes tablet breakup and dissolution |
| Sodium starch glycolate |
Superdisintegrant |
Supports rapid disintegration |
| Povidone |
Binder |
Improves granule and tablet cohesion |
| Colloidal silicon dioxide |
Glidant |
Improves powder flow and manufacturing consistency |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force |
| Hypromellose |
Film former |
Protects the tablet and improves swallowability |
| Polyethylene glycol |
Coating plasticizer |
Improves coating flexibility |
| Titanium dioxide or approved colorant |
Opacifier or color |
Supports product identification and appearance |
The excipient strategy for a commodity cetirizine tablet should prioritize robust processing over novelty. The formulation must produce consistent assay, content uniformity, dissolution, tablet hardness, friability and stability at a low unit cost. Excipients with a long pharmaceutical history and broad supplier availability are more valuable than highly differentiated materials unless they enable a distinct dosage form.
How should lactose be handled in the excipient strategy?
Lactose can be an efficient and widely used filler, but it may limit positioning for consumers seeking lactose-free products. A lactose-free version could use microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch or other suitable fillers.
A lactose-free claim can create modest differentiation in the allergy market, but it does not create a strong barrier to entry. Competing manufacturers can usually reformulate around the same positioning. The value is therefore commercial and packaging-based rather than patent-based.
Which excipients improve tablet performance?
For a standard 10 mg cetirizine tablet, the formulation has a relatively high excipient-to-active ratio because the active dose is small. The main technical risks are content uniformity, blend segregation, over-lubrication and variable disintegration.
A practical strategy is:
- Use a flow aid and low-shear blending process to reduce segregation.
- Control magnesium stearate addition time to avoid dissolution impairment.
- Use crospovidone or sodium starch glycolate at a level that supports rapid disintegration without excessive tablet swelling.
- Use a filler system that maintains compression at low tablet weight.
- Apply a thin film coat to improve appearance and swallowing without materially increasing manufacturing cost.
Direct compression can reduce processing steps, but it requires reliable powder flow and compressibility. Wet granulation can improve uniformity and tablet strength but adds equipment, energy and process controls. For a mature OTC product, direct compression is commercially attractive if the API and excipient grades support it.
What formulation patents protect WAL-ZYR?
No significant formulation patent moat is apparent for conventional WAL-ZYR cetirizine tablets. The standard tablet formulation uses established excipients and is readily reproducible by multiple generic manufacturers.
Patent protection could arise in a differentiated product only if the formulation includes a technically meaningful and non-obvious combination, such as:
- A rapid-dissolve or orally disintegrating tablet with defined dissolution performance.
- A taste-masked chewable formulation.
- A liquid formulation with improved chemical stability.
- A long-acting delivery system with clinically relevant pharmacokinetic advantages.
- A combination product with a novel ratio, release profile or treatment method.
- A manufacturing process that produces a specific particle-size distribution or impurity profile.
A routine substitution of mannitol for lactose, a different film coat or a conventional orally disintegrating tablet would generally provide weak patent differentiation. Any patent strategy would need support from comparative dissolution, stability, sensory, manufacturability or pharmacokinetic data.
When does cetirizine lose exclusivity?
Cetirizine has already lost core market exclusivity in the United States. The original Zyrtec prescription product was approved in the 1990s, and cetirizine became available over the counter in 2007. The principal composition and product patent positions have expired.
| Exclusivity element |
Status |
| Active ingredient exclusivity |
Expired |
| Original prescription product exclusivity |
Expired |
| OTC market exclusivity for cetirizine |
Expired |
| Generic cetirizine availability |
Established |
| Private-label entry |
Established |
| Current commercial barrier |
Manufacturing, distribution, quality and shelf placement |
The expiration of core exclusivity means that a new WAL-ZYR-like product does not need to overcome an incumbent patent estate. It must compete against existing low-cost products, including store brands, national brands and online sellers.
What is the Orange Book status of WAL-ZYR?
WAL-ZYR is generally not expected to have a meaningful Orange Book listing because it is a private-label OTC product rather than an innovative prescription drug with listed patents.
The Orange Book primarily identifies approved drug products, therapeutic equivalence evaluations and patent or exclusivity information relevant to approved applications. A retailer-branded OTC cetirizine product does not obtain meaningful commercial protection from Orange Book listings.
The practical result is:
- No meaningful Orange Book patent shield for WAL-ZYR.
- No Paragraph IV strategy directed at WAL-ZYR’s commercial position.
- No likely patent-based restriction on competing cetirizine tablets.
- Any litigation would more likely involve trademarks, labeling, manufacturing, quality or a separately patented formulation.
Are there Paragraph IV challenges involving WAL-ZYR?
Paragraph IV litigation is not a central risk or opportunity for conventional WAL-ZYR. Paragraph IV certifications apply to abbreviated new drug applications challenging patents listed for a reference listed drug. A private-label OTC cetirizine product generally does not function as the protected reference product in the same way as a branded prescription drug.
Competitors can enter through established generic or OTC pathways without challenging a current WAL-ZYR patent estate. The relevant competitive threat is direct substitution rather than patent litigation.
A Paragraph IV challenge could become relevant only if a manufacturer launched a separately patented cetirizine dosage form or combination product and another applicant sought approval before expiration of listed patents.
What generic entry risks exist for WAL-ZYR?
Generic entry risk is high because the product is already in a mature generic market. The principal risks are commercial rather than legal.
| Risk |
Impact on WAL-ZYR |
| Low-cost generic tablets |
High |
| Retailer switching to another contract manufacturer |
High |
| Online price competition |
High |
| API price volatility |
Moderate |
| Tablet or packaging quality failure |
High |
| Product recall |
High |
| Supply disruption |
High |
| Differentiated dosage forms |
Moderate |
| Brand-name Zyrtec promotional activity |
Low to moderate |
WAL-ZYR can defend share through retailer control, shelf placement, private-label pricing, package-size architecture and reliable replenishment. These advantages are difficult for a small generic supplier to replicate but are not patent barriers.
What excipient-based commercial opportunities exist?
The most credible opportunities are differentiated OTC presentations that address convenience, swallowability, tolerability or household use.
Lactose-free tablets
A lactose-free tablet can target consumers who prefer simplified inactive-ingredient profiles. Mannitol, microcrystalline cellulose and selected starch-based systems can replace lactose, subject to product performance and labeling requirements.
The opportunity is limited by the ease with which competitors can copy the formulation. It may still support a premium package or a targeted retailer segment.
Orally disintegrating tablets
An orally disintegrating cetirizine tablet could target consumers who have difficulty swallowing conventional tablets or want administration without water. Mannitol-based systems, crospovidone and taste-masking agents are common formulation tools.
The key development risks are cetirizine bitterness, friability, moisture sensitivity and packaging cost. Unit-dose blister packaging may be required, reducing the cost advantage over standard tablets.
Chewable tablets
Chewable cetirizine can expand use among children and adults who prefer flavored products. Flavor systems, sweeteners, taste masking and texture control become central.
A chewable product may compete more directly with liquid formulations and pediatric allergy products. It also creates greater sensory and age-appropriate labeling requirements.
Oral solution or syrup
Liquid cetirizine can support pediatric dosing and consumers who cannot swallow tablets. Excipients may include purified water, buffers, sweeteners, flavoring agents, viscosity modifiers and preservatives, depending on the formulation.
The main barriers are microbial control, chemical stability, dosing accuracy, packaging leakage and shipping weight. A preservative-free product could create differentiation, but it would require a suitable multidose or unit-dose packaging system.
Single-dose sachets and travel packaging
Small-format packaging can target travel, workplace use and emergency allergy kits. The formulation may remain conventional, but packaging can improve portability and impulse purchase.
This is a lower-risk commercial extension because it does not require a new delivery technology. The opportunity depends on retailer placement and packaging economics.
How strong is the WAL-ZYR patent estate?
The patent estate is weak as a source of exclusion and strong only in the limited sense that mature cetirizine products have established technical and regulatory knowledge.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Expired |
| Conventional tablet protection |
Weak or absent |
| Retailer brand protection |
Trademark-based |
| Novel formulation protection |
Possible but product-specific |
| Manufacturing know-how |
Moderate operational value |
| Regulatory data exclusivity |
Expired for the mature active ingredient |
| Freedom to manufacture conventional tablets |
Generally broad |
| Risk of blocking third-party patents |
Low for standard dosage forms, higher for specialized delivery systems |
The most defensible assets are trademarks, packaging design, supplier qualification, validated manufacturing processes and retailer distribution agreements. These assets may protect margin and continuity but do not prevent technical competition.
Which companies challenge WAL-ZYR commercially?
WAL-ZYR competes with several groups:
- National brand products, including Zyrtec.
- Store brands sold by CVS, Costco, Walmart, Target and grocery retailers.
- Generic cetirizine manufacturers and contract manufacturers.
- Online private-label sellers.
- Alternative antihistamine products containing loratadine, fexofenadine or levocetirizine.
- Combination allergy products containing an antihistamine and decongestant.
The strongest direct competitors are other 10 mg cetirizine tablets with comparable package counts and equivalent retail availability. Loratadine and fexofenadine create therapeutic substitution risk because consumers often select among second-generation antihistamines based on perceived sedation, duration, price and prior experience.
How does WAL-ZYR compare with competing antihistamines?
| Product category |
Main active ingredient |
Competitive strength |
Excipient opportunity |
| WAL-ZYR |
Cetirizine |
Low-cost private label and broad familiarity |
Lactose-free, ODT, chewable, liquid |
| Claritin-type products |
Loratadine |
Established brand and perceived low sedation |
Fast-melt and combination products |
| Allegra-type products |
Fexofenadine |
Perceived nonsedating profile |
Larger-format tablets and liquid |
| Xyzal-type products |
Levocetirizine |
Strong symptom-control positioning |
Premium formulations and pediatric liquid |
| Generic antihistamines |
Multiple APIs |
Lowest price |
Retailer-specific packaging and bundles |
Cetirizine’s principal commercial disadvantage is that some consumers associate it with more drowsiness than loratadine or fexofenadine. Excipient changes cannot eliminate an active-ingredient pharmacology issue. A reformulation may improve swallowability or taste but will not establish a credible nonsedating claim without supporting evidence.
What FDA regulatory issues affect WAL-ZYR?
A conventional OTC cetirizine product must comply with applicable FDA requirements for active ingredients, labeling, dosage, warnings, quality, manufacturing and packaging. The product’s regulatory pathway depends on its exact formulation and marketing history.
Key regulatory considerations include:
- Compliance with the applicable OTC antihistamine monograph or approved application.
- Correct active-ingredient and purpose labeling.
- Required warnings concerning drowsiness, alcohol and sedatives where applicable.
- Child-resistant or special packaging requirements when triggered.
- Stability data supporting shelf life.
- Dissolution and assay controls.
- Excipient labeling in the Drug Facts and inactive-ingredient sections.
- Foreign and domestic facility compliance with current good manufacturing practice.
- Advertising claims that do not exceed the approved or monograph-supported use.
A new ODT, chewable, liquid or combination product may require a different regulatory assessment from a standard tablet. The dosage form, inactive ingredients, labeling and manufacturing process can change the applicable pathway.
What licensing deals could create value?
Licensing opportunities are more likely to involve supply and technology than drug rights. Potential transactions include:
- Contract manufacturing agreements for retailer-specific cetirizine products.
- Exclusive supply agreements for directly compressible excipient blends.
- Licensing of taste-masking technology for chewable or orally disintegrating tablets.
- Packaging licenses for unit-dose, child-resistant or moisture-protective systems.
- Co-development agreements for pediatric liquids or preservative-free presentations.
- Retail distribution agreements tied to differentiated package sizes.
A license involving a standard cetirizine tablet would likely have limited bargaining power because multiple manufacturers can produce the product. A formulation or packaging license is more defensible if it produces measurable improvements in stability, sensory acceptance, dissolution or manufacturing yield.
What is the commercial outlook for WAL-ZYR?
The base case is a stable, price-sensitive OTC product with limited opportunity for premium pricing. Growth depends on expanding distribution, optimizing package counts, improving supply economics and introducing differentiated forms.
A commercially credible pipeline would rank as follows:
- Lactose-free conventional tablet, because it has low development complexity.
- Larger-count value packs, because they use established manufacturing.
- Orally disintegrating tablet, because it offers convenience but adds packaging and sensory risk.
- Chewable tablet, because it requires more extensive taste and texture development.
- Pediatric liquid, because it has broader formulation and quality controls.
- Novel controlled-release product, because cost, regulatory complexity and patent uncertainty are highest.
Revenue exposure is tied primarily to retail sell-through and retailer margin, not patent expiry. The product can retain value after any individual supplier exits because Walgreens can shift production to another qualified manufacturer.
Key Takeaways
- WAL-ZYR is a Walgreens private-label cetirizine hydrochloride OTC product, generally sold as a 10 mg tablet.
- Its active ingredient and conventional tablet technology are mature and broadly available.
- Core cetirizine patent and exclusivity protection has expired.
- The product has little or no meaningful patent-based exclusionary power.
- Standard excipients should be selected for flow, compression, disintegration, stability and cost.
- Lactose-free, orally disintegrating, chewable, liquid and travel-pack formats offer the clearest commercial extensions.
- Taste masking, moisture control and packaging are the main technical issues for differentiated dosage forms.
- Generic entry and retailer switching create high commercial risk, while Paragraph IV litigation risk is low.
- Trademarks, supply agreements, quality systems, shelf placement and package architecture are more valuable than conventional formulation patents.
- A low-complexity lactose-free tablet or value pack is the most practical near-term opportunity.
FAQs About WAL-ZYR Excipients and Commercial Strategy
Is WAL-ZYR the same drug as Zyrtec?
Yes. WAL-ZYR generally contains cetirizine hydrochloride, the same active ingredient used in Zyrtec. Inactive ingredients, tablet design, packaging and manufacturing source may differ.
Can WAL-ZYR be reformulated without new clinical trials?
Some conventional excipient substitutions may be possible without full clinical development if the product remains within the applicable regulatory pathway and demonstrates equivalent quality and performance. A new dosage form or modified-release product may require additional regulatory support.
Does a lactose-free WAL-ZYR product have patent value?
Usually not by itself. Lactose replacement is generally a formulation design choice that competitors can reproduce. Commercial value may exist through consumer positioning and retailer differentiation.
Can a cetirizine orally disintegrating tablet receive patent protection?
Potentially, but only if the formulation or manufacturing process satisfies patentability requirements and demonstrates a defensible technical distinction. Conventional ODT excipients alone may not create a strong patent position.
What is the highest-value excipient opportunity for WAL-ZYR?
For near-term commercialization, a directly compressible lactose-free formulation offers the best balance of low development risk, broad consumer appeal and manufacturing simplicity. A taste-masked ODT or chewable product has greater differentiation but also higher technical and packaging costs.
References
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). DailyMed: Current labeling for cetirizine hydrochloride tablets. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Antihistamine drug products for over-the-counter human use. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for allergies. https://www.fda.gov/
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
